Amedeo Smart

Free Medical Literature Service

 

Amedeo

Vaccines
  Free Subscription

Articles published in
Ann Intern Med
    March 2024
  1. WELLS CR, Pandey A, Moghadas SM, Fitzpatrick MC, et al
    Evaluation of Strategies for Transitioning to Annual SARS-CoV-2 Vaccination Campaigns in the United States.
    Ann Intern Med. 2024 Mar 26. doi: 10.7326/M23-2451.
    >> Share

  2. HUITS R, Grubaugh ND, Libman M, Hamer DH, et al
    Resurgence of Dengue in the Era of Genomic Surveillance and Vaccines.
    Ann Intern Med. 2024 Mar 19. doi: 10.7326/M24-0496.
    >> Share

  3. JOHANSEN ND, Vaduganathan M, Bhatt AS, Lee SG, et al
    Clinical Outcomes With Electronic Nudges to Increase Influenza Vaccination : A Prespecified Analysis of a Nationwide, Pragmatic, Registry-Based, Randomized Implementation Trial.
    Ann Intern Med. 2024 Mar 19. doi: 10.7326/M23-2638.
    >> Share

    February 2024
  4. LAINE C, Qaseem A, Moyer DV
    Putting Adult Vaccine Recommendations Into Action.
    Ann Intern Med. 2024 Feb 13. doi: 10.7326/M24-0242.
    >> Share

  5. CENTOR RM, Tenforde MW, Dawood FS
    Web Exclusive. Annals On Call - Encouraging Influenza Vaccination.
    Ann Intern Med. 2024;177:eA230004.
    >> Share

    January 2024
  6. ZERBO O, Bartlett J, Fireman B, Lewis N, et al
    Effectiveness of Recombinant Zoster Vaccine Against Herpes Zoster in a Real-World Setting.
    Ann Intern Med. 2024 Jan 9. doi: 10.7326/M23-2023.
    >> Share

  7. WU Q, Tong J, Zhang B, Zhang D, et al
    Real-World Effectiveness of BNT162b2 Against Infection and Severe Diseases in Children and Adolescents.
    Ann Intern Med. 2024 Jan 9. doi: 10.7326/M23-1754.
    >> Share

    November 2023
  8. TENFORDE MW, Dawood FS, Ellington SR, Grohskopf LA, et al
    Communicating the Value of Influenza Vaccines to Patients: Translating Vaccine Effectiveness to Acceptance.
    Ann Intern Med. 2023 Nov 28. doi: 10.7326/M23-2802.
    >> Share

    September 2023
  9. KOTTON CN
    More Protection Against Respiratory Viral Infection: Respiratory Syncytial Virus Vaccines for Adults Aged 60 Years and Older.
    Ann Intern Med. 2023 Sep 12. doi: 10.7326/M23-2196.
    >> Share

    June 2023

  10. Correction: Challenges in Estimating the Effectiveness of COVID-19 Vaccination Using Observational Data.
    Ann Intern Med. 2023 Jun 6. doi: 10.7326/L23-0217.
    >> Share

  11. AWAR M, Mylonakis E
    In older adults, an Ad26.RSV.preF-RSV preF protein vaccine reduced RSV-related lower respiratory tract disease.
    Ann Intern Med. 2023 Jun 6. doi: 10.7326/J23-0039.
    >> Share

  12. AWAR M, Mylonakis E
    In older adults, an AS01(E)-adjuvanted RSVPreF3 OA vaccine reduced RSV-related lower respiratory tract disease.
    Ann Intern Med. 2023 Jun 6. doi: 10.7326/J23-0038.
    >> Share

  13. BAJEMA KL, Berry K, Streja E, Rajeevan N, et al
    Effectiveness of COVID-19 Treatment With Nirmatrelvir-Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes.
    Ann Intern Med. 2023 Jun 6:M22-3565. doi: 10.7326/M22-3565.
    >> Share

    May 2023
  14. HULME WJ, Williamson E, Horne EMF, Green A, et al
    Challenges in Estimating the Effectiveness of COVID-19 Vaccination Using Observational Data.
    Ann Intern Med. 2023 May 2:M21-4269. doi: 10.7326/M21-4269.
    >> Share

    March 2023
  15. WANG TY, Wahed AS, Morris A, Kreuziger LB, et al
    Effect of Thromboprophylaxis on Clinical Outcomes After COVID-19 Hospitalization.
    Ann Intern Med. 2023 Mar 21. doi: 10.7326/M22-3350.
    >> Share

  16. WAN EYF, Yan VKC, Mok AHY, Wang B, et al
    Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Hospitalized Patients With COVID-19 : A Target Trial Emulation Study.
    Ann Intern Med. 2023 Mar 14. doi: 10.7326/M22-3057.
    >> Share

    December 2022

  17. Correction: Risk Heterogeneity and the Illusion of Waning Vaccine Efficacy.
    Ann Intern Med. 2022 Dec 27. doi: 10.7326/L22-0508.
    >> Share

  18. DRYDEN-PETERSON S, Kim A, Kim AY, Caniglia EC, et al
    Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System : A Population-Based Cohort Study.
    Ann Intern Med. 2022 Dec 13. doi: 10.7326/M22-2141.
    >> Share

    October 2022
  19. ROOZEN GVT, Prins MLM, van Binnendijk R, den Hartog G, et al
    Safety and Immunogenicity of Intradermal Fractional Dose Administration of the mRNA-1273 Vaccine: A Proof-of-Concept Study.
    Ann Intern Med. 2022 Oct 25. doi: 10.7326/M22-2089.
    >> Share

  20. IOANNOU GN, Bohnert ASB, O'Hare AM, Boyko EJ, et al
    Effectiveness of mRNA COVID-19 Vaccine Boosters Against Infection, Hospitalization, and Death: A Target Trial Emulation in the Omicron (B.1.1.529) Variant Era.
    Ann Intern Med. 2022 Oct 11. doi: 10.7326/M22-1856.
    >> Share

  21. GODDARD K, Hanson KE, Lewis N, Weintraub E, et al
    Incidence of Myocarditis/Pericarditis Following mRNA COVID-19 Vaccination Among Children and Younger Adults in the United States.
    Ann Intern Med. 2022 Oct 4. doi: 10.7326/M22-2274.
    >> Share

    September 2022
  22. TAN CY, Chiew CJ, Lee VJ, Ong B, et al
    Effectiveness of a Fourth Dose of COVID-19 mRNA Vaccine Against Omicron Variant Among Elderly People in Singapore.
    Ann Intern Med. 2022 Sep 13. doi: 10.7326/M22-2042.
    >> Share

    August 2022
  23. BOTTON J, Jabagi MJ, Bertrand M, Baricault B, et al
    Risk for Myocardial Infarction, Stroke, and Pulmonary Embolism Following COVID-19 Vaccines in Adults Younger Than 75 Years in France.
    Ann Intern Med. 2022 Aug 23. doi: 10.7326/M22-0988.
    >> Share

  24. BROPHY JM
    mRNA COVID-19 vaccines were linked to myocarditis at 28 d (0.15 to 10 excess events/100 000 vaccinated persons).
    Ann Intern Med. 2022 Aug 2. doi: 10.7326/J22-0057.
    >> Share

  25. AISENBERG GM
    In persons at risk for poor vaccination response or COVID-19 exposure, tixagevimab + cilgavimab reduced COVID-19.
    Ann Intern Med. 2022 Aug 2. doi: 10.7326/J22-0056.
    >> Share

    July 2022
  26. FORSTER D
    COVID-19 diagnosis, but not vaccination, was linked to increased risk for immune-mediated neurologic events.
    Ann Intern Med. 2022 Jul 5. doi: 10.7326/J22-0048.
    >> Share

  27. FOLLMANN D, Janes HE, Buhule OD, Zhou H, et al
    Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial.
    Ann Intern Med. 2022 Jul 5. doi: 10.7326/M22-1300.
    >> Share

    May 2022
  28. ROSENBLUM HG, Lewis RM, Gargano JW, Querec TD, et al
    Human Papillomavirus Vaccine Impact and Effectiveness Through 12 Years After Vaccine Introduction in the United States, 2003 to 2018.
    Ann Intern Med. 2022 May 17. doi: 10.7326/M21-3798.
    >> Share

  29. PERKINS RB, Saslow D, Oliver K
    Long-Term Effectiveness of Human Papillomavirus Vaccination: Implications for Future Reduction in Cancer.
    Ann Intern Med. 2022 May 17. doi: 10.7326/M22-1309.
    >> Share

  30. ASSOUMOU SA, Peterson A, Ginman E, James T, et al
    Addressing Inequities in SARS-CoV-2 Vaccine Uptake: The Boston Medical Center Health System Experience.
    Ann Intern Med. 2022 May 17. doi: 10.7326/M22-0028.
    >> Share

  31. KRYCHTIUK KA, Newby LK
    Moderna COVID-19 vaccine was linked to myocarditis or myopericarditis at 28 d (4.2 events/100 000 persons).
    Ann Intern Med. 2022 May 3. doi: 10.7326/J22-0021.
    >> Share

  32. GRANWEHR BP
    In adults who had not had COVID-19, Novavax vaccine had 90% efficacy at >/=7 d after the second dose.
    Ann Intern Med. 2022 May 3. doi: 10.7326/J22-0028.
    >> Share

  33. ZAHRADKA I, Petr V, Modos I, Magicova M, et al
    Association Between SARS-CoV-2 Messenger RNA Vaccines and Lower Infection Rates in Kidney Transplant Recipients : A Registry-Based Report.
    Ann Intern Med. 2022 May 3. doi: 10.7326/M21-2973.
    >> Share

    April 2022
  34. KOTTON CN
    Belt and Suspenders: Vaccines and Tixagevimab/Cilgavimab for Prevention of COVID-19 in Immunocompromised Patients.
    Ann Intern Med. 2022 Apr 12. doi: 10.7326/M22-1026.
    >> Share

  35. ROTHBERG MB
    Community-Acquired Pneumonia.
    Ann Intern Med. 2022 Apr 12. doi: 10.7326/AITC202204190.
    >> Share

    March 2022
  36. ZHENG C, Duffy J, Liu IA, Sy LS, et al
    Risk for Shoulder Conditions After Vaccination: A Population-Based Study Using Real-World Data.
    Ann Intern Med. 2022 Mar 22. doi: 10.7326/M21-3023.
    >> Share

  37. LARSON EB, Nelson JC
    In older adults, use of a recombinant zoster vaccine was associated with Guillain-Barre syndrome.
    Ann Intern Med. 2022 Mar 1. doi: 10.7326/J22-0010.
    >> Share

  38. SILVESTRI EG, Borzak S
    In patients with MI or high-risk coronary disease, influenza vaccination reduced CV events at 12 mo.
    Ann Intern Med. 2022 Mar 1. doi: 10.7326/J22-0006.
    >> Share

    February 2022
  39. GAZIT S, Shlezinger R, Perez G, Lotan R, et al
    The Incidence of SARS-CoV-2 Reinfection in Persons With Naturally Acquired Immunity With and Without Subsequent Receipt of a Single Dose of BNT162b2 Vaccine : A Retrospective Cohort Study.
    Ann Intern Med. 2022 Feb 15. doi: 10.7326/M21-4130.
    >> Share

  40. HVIID A, Hansen JV, Thiesson EM, Wohlfahrt J, et al
    Association of AZD1222 and BNT162b2 COVID-19 Vaccination With Thromboembolic and Thrombocytopenic Events in Frontline Personnel : A Retrospective Cohort Study.
    Ann Intern Med. 2022 Feb 1. doi: 10.7326/M21-2452.
    >> Share

  41. KANG M, Yi Y, Li Y, Sun L, et al
    Effectiveness of Inactivated COVID-19 Vaccines Against Illness Caused by the B.1.617.2 (Delta) Variant During an Outbreak in Guangdong, China : A Cohort Study.
    Ann Intern Med. 2022 Feb 1. doi: 10.7326/M21-3509.
    >> Share

  42. CHANG R
    Web Exclusive. Annals for Hospitalists Inpatient Notes - Another Way That Hospitalists Can Fight COVID-19.
    Ann Intern Med. 2022;175:HO2-HO3.
    >> Share

    January 2022
  43. TSUN LAI FT, Li X, Peng K, Huang L, et al
    Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine : A Case-Control Study.
    Ann Intern Med. 2022 Jan 25. doi: 10.7326/M21-3700.
    >> Share

  44. QASEEM A, Yost J, Etxeandia-Ikobaltzeta I, Forciea MA, et al
    What Is the Antibody Response and Role in Conferring Natural Immunity After SARS-CoV-2 Infection? Rapid, Living Practice Points From the American College of Physicians (Version 2).
    Ann Intern Med. 2022 Jan 25. doi: 10.7326/M21-3272.
    >> Share

  45. SEE I, Lale A, Marquez P, Streiff MB, et al
    Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination-United States, December 2020 to August 2021.
    Ann Intern Med. 2022 Jan 18. doi: 10.7326/M21-4502.
    >> Share

  46. CAILLARD S, Thaunat O, Benotmane I, Masset C, et al
    Antibody Response to a Fourth Messenger RNA COVID-19 Vaccine Dose in Kidney Transplant Recipients: A Case Series.
    Ann Intern Med. 2022 Jan 11. doi: 10.7326/L21-0598.
    >> Share

    December 2021
  47. IOANNOU GN, Locke ER, O'Hare AM, Bohnert ASB, et al
    COVID-19 Vaccination Effectiveness Against Infection or Death in a National U.S. Health Care System : A Target Trial Emulation Study.
    Ann Intern Med. 2021 Dec 21. doi: 10.7326/M21-3256.
    >> Share

  48. FAY MP, Hunsberger S, Follmann D
    Risk Heterogeneity and the Illusion of Waning Vaccine Efficacy.
    Ann Intern Med. 2021 Dec 21. doi: 10.7326/M21-3609.
    >> Share

  49. ANAND S, Montez-Rath ME, Han J, Garcia P, et al
    SARS-CoV-2 Vaccine Antibody Response and Breakthrough Infection in Patients Receiving Dialysis.
    Ann Intern Med. 2021 Dec 14. doi: 10.7326/M21-4176.
    >> Share

  50. LAINE C, Moyer DV, Cotton D
    COVID-19: Challenging Clinical Questions.
    Ann Intern Med. 2021 Dec 14. doi: 10.7326/M21-4611.
    >> Share


  51. Correction: Antibody Responses After SARS-CoV-2 mRNA Vaccination in Adults With Inflammatory Bowel Disease.
    Ann Intern Med. 2021;174:1780.
    >> Share

    November 2021
  52. KUMAR D, Ferreira VH, Hall VG, Hu Q, et al
    Neutralization of SARS-CoV-2 Variants in Transplant Recipients After Two and Three Doses of mRNA-1273 Vaccine : Secondary Analysis of a Randomized Trial.
    Ann Intern Med. 2021 Nov 23. doi: 10.7326/M21-3480.
    >> Share

  53. CHO BH, Weinbaum C, Tsai Y, Koppaka R, et al
    Influenza Vaccine Uptake and Missed Opportunities Among the Medicare-Covered Population With High-Risk Conditions During the 2018 to 2019 Influenza Season : A Retrospective Cohort Study.
    Ann Intern Med. 2021 Nov 16. doi: 10.7326/M21-1550.
    >> Share

  54. SARPATWARI A, Pandya A, Hyle EP, Persad G, et al
    COVID-19 Vaccine Boosters for All Adults: An Optimal U.S. Approach?
    Ann Intern Med. 2021 Nov 9. doi: 10.7326/M21-3927.
    >> Share

  55. UYEKI TM
    Influenza.
    Ann Intern Med. 2021 Nov 9. doi: 10.7326/AITC202111160.
    >> Share

  56. MAKI DG
    Recommendations were made for diagnosis and management of allergic reactions to COVID-19 vaccines.
    Ann Intern Med. 2021 Nov 2. doi: 10.7326/ACPJ202111160.
    >> Share

  57. GRANWEHR BP
    BioNTech/Pfizer vaccine after Oxford/AZ vaccine increased immune response vs. no second vaccine.
    Ann Intern Med. 2021 Nov 2. doi: 10.7326/ACPJ202111160.
    >> Share

  58. SACKS HS
    The Novavax vaccine had 90% efficacy against COVID-19 >/=7 d after the second dose.
    Ann Intern Med. 2021 Nov 2. doi: 10.7326/ACPJ202111160.
    >> Share

  59. DORFMAN AL, Murthy VL
    Web Exclusive. Annals for Hospitalists Inpatient Notes - Myocarditis After Vaccination for SARS-CoV-2.
    Ann Intern Med. 2021;174:HO2-HO3.
    >> Share

    October 2021
  60. HIMMELSTEIN J, Himmelstein DU, Woolhandler S, Dickman S, et al
    COVID-19-Related Care for Hispanic Elderly Adults With Limited English Proficiency.
    Ann Intern Med. 2021 Oct 26. doi: 10.7326/M21-2900.
    >> Share

  61. NOVAZZI F, Taborelli S, Baj A, Focosi D, et al
    Asymptomatic SARS-CoV-2 Vaccine Breakthrough Infections in Health Care Workers Identified Through Routine Universal Surveillance Testing.
    Ann Intern Med. 2021 Oct 19. doi: 10.7326/M21-3486.
    >> Share

  62. MELMED GY, Botwin GJ, Sobhani K, Li D, et al
    Antibody Responses After SARS-CoV-2 mRNA Vaccination in Adults With Inflammatory Bowel Disease.
    Ann Intern Med. 2021 Oct 12. doi: 10.7326/M21-2483.
    >> Share

  63. LAINE C, Cotton D, Moyer DV
    COVID-19: Clinical and Public Health Implications of SARS-CoV-2 Immunology.
    Ann Intern Med. 2021 Oct 12. doi: 10.7326/M21-3840.
    >> Share

  64. DELANEY SW, Essien UR, Navathe A
    Disparate Impact: How Colorblind Policies Exacerbate Black-White Health Inequities.
    Ann Intern Med. 2021;174:1450-1451.
    >> Share

    September 2021
  65. CURTIS JR, Cofield SS, Bridges SL Jr, Bassler J, et al
    The Safety and Immunologic Effectiveness of the Live Varicella-Zoster Vaccine in Patients Receiving Tumor Necrosis Factor Inhibitor Therapy : A Randomized Controlled Trial.
    Ann Intern Med. 2021 Sep 28. doi: 10.7326/M20-6928.
    >> Share

  66. REIF J, Heun-Johnson H, Tysinger B, Lakdawalla D, et al
    Measuring the COVID-19 Mortality Burden in the United States : A Microsimulation Study.
    Ann Intern Med. 2021 Sep 21. doi: 10.7326/M21-2239.
    >> Share

  67. MOGHADAS SM, Sah P, Shoukat A, Meyers LA, et al
    Population Immunity Against COVID-19 in the United States.
    Ann Intern Med. 2021 Sep 14. doi: 10.7326/M21-2721.
    >> Share

    August 2021
  68. PALTIEL AD, Schwartz JL
    Assessing COVID-19 Prevention Strategies to Permit the Safe Opening of Residential Colleges in Fall 2021.
    Ann Intern Med. 2021 Aug 31. doi: 10.7326/M21-2965.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016